Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of ALXN2060 in Japanese Participants with Symptomatic ATTR-CM
jRCT2071200059Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acoramidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Alexion Pharmaceuticals. Primary endpoints: Change from Baseline to Month 12 in 6-minute walk test distance and All-cause mortality and cardiovascular-related hospitalization over 30 months. Started Nov 2020; status: completed.
02
Drugs
acoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT2071200059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071200059.